ACADIA Pharmaceuticals Stock Forecast, Price & News

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ACADIA Pharmaceuticals in the last twelve months. There are currently 1 hold rating, 14 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ACADIA Pharmaceuticals stock.
View analyst ratings for ACADIA Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given ACADIA Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but ACADIA Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

ACADIA Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for ACADIA Pharmaceuticals.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) issued its quarterly earnings data on Tuesday, February, 23rd. The biopharmaceutical company reported ($0.42) EPS for the quarter, beating analysts' consensus estimates of ($0.47) by $0.05. ACADIA Pharmaceuticals had a negative trailing twelve-month return on equity of 40.35% and a negative net margin of 63.92%.
View ACADIA Pharmaceuticals' earnings history.

ACADIA Pharmaceuticals' stock was trading at $36.87 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ACAD shares have increased by 24.3% and is now trading at $45.82.
View which stocks have been most impacted by COVID-19.

16 analysts have issued 12 month price targets for ACADIA Pharmaceuticals' shares. Their forecasts range from $42.00 to $72.00. On average, they expect ACADIA Pharmaceuticals' share price to reach $62.27 in the next twelve months. This suggests a possible upside of 35.9% from the stock's current price.
View analysts' price targets for ACADIA Pharmaceuticals or view top-rated stocks among Wall Street analysts.

8 employees have rated ACADIA Pharmaceuticals CEO Steve Davis on Glassdoor.com. Steve Davis has an approval rating of 88% among ACADIA Pharmaceuticals' employees.

Some companies that are related to ACADIA Pharmaceuticals include Takeda Pharmaceutical (TKPYY), BeiGene (BGNE), MERCK Kommanditgesellschaft auf Aktien (MKGAF), Genmab A/S (GMAB), Horizon Therapeutics Public (HZNP), UCB (UCBJF), Genmab A/S (GNMSF), Catalent (CTLT), Royalty Pharma (RPRX), Alnylam Pharmaceuticals (ALNY), Ono Pharmaceutical (OPHLF), CureVac (CVAC), Elanco Animal Health (ELAN), BioMarin Pharmaceutical (BMRN) and Zai Lab (ZLAB).
View all of ACAD's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other ACADIA Pharmaceuticals investors own include Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Sarepta Therapeutics (SRPT), Pfizer (PFE), Tesla (TSLA), Alibaba Group (BABA), Amarin (AMRN), Advanced Micro Devices (AMD) and Exelixis (EXEL).

ACADIA Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACAD."

ACADIA Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include FMR LLC (12.25%), Price T Rowe Associates Inc. MD (4.96%), BlackRock Inc. (4.55%), Janus Henderson Group PLC (3.20%), Avoro Capital Advisors LLC (1.23%) and First Trust Advisors LP (1.02%). Company insiders that own ACADIA Pharmaceuticals stock include Austin D Kim, Bros Advisors Lp Baker, Elena Ridloff, Eric Alejandro Miller, James M Daly, Laura Brege, Michael J Yang, Srdjan R Stankovic and Stephen Davis.
View institutional ownership trends for ACADIA Pharmaceuticals.

ACAD stock was sold by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Janus Henderson Group PLC, FMR LLC, Squarepoint Ops LLC, First Trust Advisors LP, Renaissance Technologies LLC, Engineers Gate Manager LP, and Charles Schwab Investment Management Inc.. Company insiders that have sold ACADIA Pharmaceuticals company stock in the last year include Austin D Kim, Elena Ridloff, James M Daly, Michael J Yang, Srdjan R Stankovic, and Stephen Davis.
View insider buying and selling activity for ACADIA Pharmaceuticals or view top insider-selling stocks.

ACAD stock was acquired by a variety of institutional investors in the last quarter, including Avoro Capital Advisors LLC, Norges Bank, Avidity Partners Management LP, Great Lakes Advisors LLC, Jennison Associates LLC, Artisan Partners Limited Partnership, The Manufacturers Life Insurance Company , and Thornburg Investment Management Inc..
View insider buying and selling activity for ACADIA Pharmaceuticals or or view top insider-buying stocks.

Shares of ACAD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ACAD stock can currently be purchased for approximately $45.82.

ACADIA Pharmaceuticals has a market capitalization of $7.33 billion and generates $339.08 million in revenue each year. The biopharmaceutical company earns $-235,260,000.00 in net income (profit) each year or ($1.60) on an earnings per share basis.

ACADIA Pharmaceuticals employs 580 workers across the globe.

The official website for ACADIA Pharmaceuticals is www.acadia-pharm.com.

ACADIA Pharmaceuticals is headquartered at 3611 VALLEY CENTRE DRIVE SUITE 300, SAN DIEGO CA, 92130.

ACADIA Pharmaceuticals' mailing address is 3611 VALLEY CENTRE DRIVE SUITE 300, SAN DIEGO CA, 92130. The biopharmaceutical company can be reached via phone at 858-558-2871 or via email at [email protected]